RINGPU(300119)
Search documents
动物保健板块1月16日涨0.93%,生物股份领涨,主力资金净流入1.12亿元
Zheng Xing Xing Ye Ri Bao· 2026-01-16 08:49
Core Viewpoint - The animal health sector experienced a rise of 0.93% on January 16, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4101.91, down 0.26% [1]. - The Shenzhen Component Index closed at 14281.08, down 0.18% [1]. Group 2: Individual Stock Performance - BioShares (600201) led the gains with a closing price of 17.61, up 3.53%, and a trading volume of 480,000 shares, amounting to a transaction value of 840 million yuan [1]. - Other notable performers included: - Huisheng Bio (300871) at 26.03, up 1.36%, with a transaction value of 434 million yuan [1]. - Xianfeng Holdings (002141) at 3.76, up 1.35%, with a transaction value of 8.13 million yuan [1]. - Ruipu Bio (300119) at 20.15, up 0.90%, with a transaction value of 110 million yuan [1]. - Shunlian Bio (688098) at 9.60, up 0.63%, with a transaction value of 40.84 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 112 million yuan from institutional investors, while retail investors experienced a net outflow of 68.65 million yuan [2]. - The capital flow for individual stocks showed: - BioShares had a net inflow of 75.95 million yuan from institutional investors [3]. - Huisheng Bio had a net inflow of 19.63 million yuan from institutional investors [3]. - Xianfeng Holdings had a net inflow of 16.40 million yuan from institutional investors [3].
瑞普生物荣获“天津市2025年度绿色工厂”认定
Zheng Quan Shi Bao Wang· 2026-01-15 07:45
Group 1 - The core viewpoint of the news is that Reap Bio has been recognized as a "Green Factory" for 2025 by the Tianjin Municipal Bureau of Industry and Information Technology, highlighting its leadership in promoting green transformation in the industry [1] - The recognition reflects Reap Bio's strong manufacturing capabilities and its commitment to integrating green and low-carbon development into its core business strategy since its establishment [1] - The evaluation process for the recognition included stringent requirements on energy consumption levels, environmental indicators, and green management systems, prioritizing enterprises with a solid foundation in green low-carbon development [1] Group 2 - In recent years, Reap Bio has aimed to build "smart factories and digital factories," implementing a lean green management system and increasing investments in the integration of intelligence, digitalization, and greening [2] - The company has embedded low-carbon standards throughout the entire process from raw material procurement to production and finished product delivery, utilizing smart production equipment and real-time monitoring systems for energy consumption and emissions [2] - Reap Bio's practices align with the national "14th Five-Year Plan" recommendations to accelerate the high-end, intelligent, and green development of the manufacturing industry, and the company plans to continue its commitment to sustainable development and contribute to high-quality manufacturing and carbon neutrality goals [2]
动物保健板块1月14日跌0.44%,海利生物领跌,主力资金净流出1.4亿元
Zheng Xing Xing Ye Ri Bao· 2026-01-14 08:44
Market Overview - The animal health sector experienced a decline of 0.44% on January 14, with Haili Biological leading the drop [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.39, up 10.65% on a trading volume of 112,300 shares and a turnover of 118 million yuan [1] - Huisheng Biological (code: 300871) closed at 25.52, up 1.84% with a trading volume of 270,100 shares and a turnover of 696 million yuan [1] - Major decliners included: - Haili Biological (code: 603718) closed at 6.55, down 1.65% with a trading volume of 237,400 shares and a turnover of 157 million yuan [2] - Zhongmu Co., Ltd. (code: 600195) closed at 7.92, down 1.61% with a trading volume of 201,400 shares and a turnover of 161 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 140 million yuan from institutional investors, while retail investors experienced a net inflow of 52.14 million yuan [2] - The detailed capital flow for selected stocks showed: - Huisheng Biological had a net inflow of 23.06 million yuan from institutional investors [3] - ST Green Kang (code: 002868) faced a significant net outflow of 5.87 million yuan from institutional investors [3]
瑞普生物:截至2026年1月9日股东总户数25854户
Zheng Quan Ri Bao Wang· 2026-01-13 11:12
Group 1 - The core point of the article is that Reap Bio (300119) has reported a total of 25,854 shareholders as of January 9, 2026 [1]
动物保健板块1月13日涨1.09%,回盛生物领涨,主力资金净流入3499.36万元
Zheng Xing Xing Ye Ri Bao· 2026-01-13 08:57
Core Insights - The animal health sector experienced a rise of 1.09% on January 13, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Stock Performance - Huisheng Biological (300871) closed at 25.06, up 8.39%, with a trading volume of 276,700 shares and a transaction value of 700 million [1] - Other notable performers included: - Qudongli (920275) at 65.6, up 3.99% [1] - Haili Biological (603718) at 6.66, up 1.99% [1] - Xianfeng Holdings (002141) at 3.77, up 1.34% [1] - Shunlian Biological (688098) at 9.78, up 1.03% [1] Capital Flow - The animal health sector saw a net inflow of 34.99 million from institutional investors, while retail investors contributed a net inflow of 30.94 million [2] - However, speculative funds experienced a net outflow of 65.94 million [2] Individual Stock Capital Flow - Major net inflows were observed in: - Biological Shares (600201) with a net inflow of 39.54 million [3] - Jinhe Biological (002688) with a net inflow of 13.45 million [3] - Xianfeng Holdings (002141) with a net inflow of 10.20 million [3] - Conversely, significant net outflows were noted in: - Biological Shares (600201) with a net outflow of 48.25 million from speculative funds [3] - Jinhe Biological (002688) with a net outflow of 1.46 million from retail investors [3]
动物疫苗概念下跌0.04%,主力资金净流出14股
Zheng Quan Shi Bao Wang· 2026-01-12 09:23
Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]
东方证券农林牧渔行业周报(20260105-20260111):12月猪企出栏延续增量降重-20260110
Orient Securities· 2026-01-10 14:56
Investment Rating - The report maintains a "Positive" investment rating for the agricultural industry [5] Core Insights - The report highlights a structural shortage in the pig market, with expectations for a price turning point in Q2 2026 due to ongoing capacity reduction and favorable policies [3][9] - The report emphasizes the potential for long-term performance improvement in the pig farming sector, driven by policy and market forces [3][9] Summary by Sections Investment Recommendations - The report recommends focusing on the pig farming sector, anticipating a price recovery in Q2 2026, with suggested stocks including Muyuan Foods (002714, Buy), Wens Foodstuff Group (300498, Buy), and Shennong Group (605296, Not Rated) [3] - It also suggests looking at the animal health sector, which may benefit from profit transmission down the supply chain, with recommended stocks including Haida Group (002311, Buy) and Reap Bio (300119, Not Rated) [3] - In the planting chain, the report notes a confirmed upward trend in grain prices, highlighting investment opportunities in large-scale planting, with suggested stocks including Suqian Agricultural Development (601952, Not Rated) and Beidahuang (600598, Not Rated) [3] - The pet food sector is also highlighted, with growth driven by increasing domestic brand recognition and overseas market expansion, recommending stocks such as Guibao Pet (301498, Not Rated) and Zhongchong Co. (002891, Not Rated) [3] Industry Fundamentals - The report indicates that December saw a continued increase in pig output, with 13 listed pig companies collectively reporting an output of 18.72 million heads, a month-on-month increase of 7.11% and a year-on-year increase of 6.8% [13] - The average selling price for pigs in December remained low, with a range from 10.66 yuan/kg to 12.54 yuan/kg, and an overall average around 11.5 yuan/kg [15] - The average weight of pigs sold in December was 124.85 kg, reflecting a decrease of 1.8 kg from the previous month, indicating a trend of accelerated inventory reduction [15][16] Market Trends - The report notes that the natural rubber market is experiencing price strength, with futures prices reaching 16,030 yuan/ton, a week-on-week increase of 2.72% [47] - The report also highlights a stable upward trend in grain prices, with corn and wheat prices showing slight declines while soybean meal prices have increased [37]
动物保健板块1月9日涨1.55%,生物股份领涨,主力资金净流出2738.79万元
Zheng Xing Xing Ye Ri Bao· 2026-01-09 08:52
Core Viewpoint - The animal health sector experienced a rise of 1.55% on January 9, with significant contributions from leading stocks like Biological Shares, which surged by 4.76% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4120.43, up by 0.92%, while the Shenzhen Component Index closed at 14120.15, up by 1.15% [1]. - The top-performing stock in the animal health sector was Biological Shares (600201), closing at 17.40 with a gain of 4.76% and a trading volume of 683,900 shares, amounting to a transaction value of 1.179 billion yuan [1]. Group 2: Stock Performance Summary - Other notable stocks included: - Shunlian Biological (688098) at 9.67, up by 1.90% with a trading volume of 64,900 shares [1]. - Zhongmu Shares (600195) at 8.10, up by 1.25% with a trading volume of 138,100 shares [1]. - Ruipu Biological (300119) at 19.90, up by 1.12% with a trading volume of 154,700 shares [1]. - Haili Biological (603718) at 6.48, up by 0.78% with a trading volume of 124,600 shares [1]. Group 3: Capital Flow Analysis - The animal health sector saw a net outflow of 27.3879 million yuan from institutional investors, while retail investors contributed a net inflow of 90.8993 million yuan [2]. - The capital flow for specific stocks showed: - Haili Biological had a net inflow of 10.2913 million yuan from institutional investors [3]. - Jinhe Biological experienced a net inflow of 2.8449 million yuan from institutional investors [3]. - *ST Green Kang (002868) had a net inflow of 1.8780 million yuan from institutional investors [3].
南非面临世上最严重口蹄疫,国内厂商有望承接海外需求
Xuan Gu Bao· 2026-01-08 23:28
Group 1 - South Africa is experiencing the most severe foot-and-mouth disease outbreak in its history, with rapid virus transmission and strong infectivity, posing an unprecedented disaster for the livestock industry [1] - The outbreak began in April 2025 in KwaZulu-Natal province and has spread to other key agricultural areas, prompting the South African Department of Agriculture to procure vaccines for emergency vaccination of 930,000 animals [1] - The outbreak highlights the importance of global animal disease prevention and presents overseas market expansion opportunities for domestic animal health companies with technological advantages [1] Group 2 - The animal health industry has a tightly linked upstream and downstream, with upstream raw material drug companies providing essential support for vaccine production, while downstream demand from farming recovery and overseas epidemic prevention needs drive industry growth [2] - Companies like Reap Bio focus on veterinary biological products, including foot-and-mouth disease vaccines, covering multiple sectors such as pigs, poultry, and pets [3] - Bio Company is a leading domestic animal health enterprise with designated production qualifications for strong immunity foot-and-mouth disease vaccines, consistently ranking first in the industry for vaccine batch approvals [4]
动物保健板块1月8日涨0.99%,生物股份领涨,主力资金净流入1012.62万元





Zheng Xing Xing Ye Ri Bao· 2026-01-08 08:57
Core Viewpoint - The animal health sector experienced a 0.99% increase on January 8, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4082.98, down 0.07%, and the Shenzhen Component Index closed at 13959.48, down 0.51% [1]. - The animal health sector stocks showed varied performance, with BioShares leading the gains at 3.10% [1]. Group 2: Stock Performance - Key stocks in the animal health sector included: - BioShares (600201) closed at 16.61 with a 3.10% increase and a trading volume of 517,400 shares, totaling 853 million yuan [1]. - Huisheng Biological (300871) closed at 22.46, up 2.23%, with a trading volume of 86,000 shares, totaling 193 million yuan [1]. - Dayu Biological (920970) closed at 8.02, up 2.17%, with a trading volume of 19,900 shares, totaling 15.81 million yuan [1]. - Other notable stocks included PlaiKe (603566) and Shunlian Biological (688098), with increases of 1.90% and 1.71% respectively [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 10.1262 million yuan from institutional investors, while retail investors contributed a net inflow of 37.4241 million yuan [2]. - Notably, the main funds showed a net outflow of 47.5503 million yuan from speculative funds [2]. Group 4: Detailed Capital Flow by Stock - BioShares (600201) had a net inflow of 40.3094 million yuan from main funds, while it experienced a net outflow of 8.4352 million yuan from speculative funds [3]. - Gold River Biological (002688) saw a net inflow of 13.2219 million yuan from main funds, with a net outflow of 3.8181 million yuan from speculative funds [3]. - ST Green Health (002868) had a net inflow of 9.7760 million yuan from main funds, but a significant net outflow of 20.7609 million yuan from speculative funds [3].